Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner, Optel Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration, as well as to ensure final device performance, compliance with all applicable regulatory standards, and optimal manufacturability to meet cost targets and anticipated user demand. “We chose Lighthouse because of its accomplished history of taking innovative products like our i/Blue System and applying its cross-functional expertise in optics, electronics, software and mechanical design to move into commercial manufacturing,” said Imagin’s Director of Engineering and Quality, Mike Vergano. “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”
To view the full press release, visit https://ibn.fm/uBRbZ
Imagin Medical Inc.
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. Learn more at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork